Wegovy Pill Approved in the UK: What the MHRA's Decision Means for Patients

The UK's medicines regulator, the MHRA, has approved the first oral version of Wegovy (semaglutide) for weight management, making the UK the first country in Europe to authorise a GLP-1 weight loss tablet. This marks a significant milestone for obesity treatment and could provide a more convenient alternative for people who are unwilling or unable to use injections.

What Is the Wegovy Pill?

The new Wegovy tablet contains semaglutide, the same active ingredient found in injectable Wegovy. Like the injection, it works by mimicking the GLP-1 hormone, helping to reduce appetite, increase feelings of fullness and support weight loss when combined with a reduced-calorie diet and increased physical activity.

Unlike the weekly Wegovy injection, the tablet is taken once daily.

Who Can Use It?

The MHRA has approved Wegovy tablets for adults with:

• A BMI of 30 kg/m² or above (obesity), or
• A BMI of 27 kg/m² to below 30 kg/m² (overweight) with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea or cardiovascular disease.

How Effective Is Oral Wegovy?

Approval was based on clinical trial data showing significant weight loss in adults living with obesity or overweight when semaglutide tablets were used alongside lifestyle changes. Novo Nordisk's OASIS programme demonstrated meaningful reductions in body weight compared with placebo.

Reports indicate participants achieved weight loss comparable to that seen with some injectable GLP-1 treatments, making the tablet a potentially attractive option for many patients.

Will It Replace Wegovy Injections?

Not necessarily.

Many patients are comfortable with a once-weekly injection and may prefer not having to remember a daily tablet. Others may welcome a needle-free option.

The tablet also comes with specific administration requirements. It must be taken on an empty stomach after fasting, and users must wait before eating, drinking or taking other medications.

For some patients, this may be less convenient than a weekly injection.

When Will It Be Available?

Novo Nordisk has indicated that Wegovy tablets are expected to become available through private prescription services within weeks following MHRA approval.

However, the treatment is not yet available through the NHS. A separate assessment by the National Institute for Health and Care Excellence (NICE) will be required before NHS funding can be considered.

What Could This Mean for the UK Weight Loss Market?

The approval of oral Wegovy could increase competition within the weight loss market and provide patients with greater choice. Some people who have been hesitant to start injectable treatments may be more willing to try a tablet instead.

The move may also increase competition among online pharmacies and weight loss providers, which could eventually influence pricing and availability across the sector. With millions of people in the UK eligible for obesity treatment, demand is expected to remain strong.

Final Thoughts

The approval of Wegovy tablets is one of the most significant developments in obesity treatment in recent years. For the first time, UK patients will have access to a GLP-1 weight loss medication in tablet form, offering an alternative to weekly injections.

Whether patients choose the tablet or injection route will likely come down to personal preference, lifestyle and cost. As more information becomes available on pricing and pharmacy availability, we'll continue to monitor the market and update our comparisons.

Compare Wegovy Prices

Looking for the latest Wegovy prices from UK online pharmacies? Use PriceMyMeds to compare providers, discounts and availability in one place.

⚠️ Always speak to a healthcare professional before starting or changing any prescription medication. PriceMyMeds provides price comparison only - not medical advice.